Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives Average Rating of “Hold” from Analysts

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) has received an average rating of “Hold” from the six analysts that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $35.00.

Several research firms have recently weighed in on CALT. Lifesci Capital cut Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 28th. HC Wainwright restated a “neutral” rating and set a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Citigroup restated a “neutral” rating and set a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Friday, May 31st. Stifel Nicolaus reaffirmed a “hold” rating and issued a $40.00 price objective (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $39.00 price objective (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th.

Hedge Funds Weigh In On Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. purchased a new stake in Calliditas Therapeutics AB (publ) (NASDAQ:CALT) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 980 shares of the company’s stock, valued at approximately $25,000. 2.83% of the stock is currently owned by institutional investors.

Calliditas Therapeutics AB (publ) Stock Performance

Calliditas Therapeutics AB (publ) stock opened at $38.19 on Friday. Calliditas Therapeutics AB has a 12-month low of $15.25 and a 12-month high of $41.90. The company has a quick ratio of 2.62, a current ratio of 2.69 and a debt-to-equity ratio of 8.46. The business’s 50-day moving average price is $37.00 and its two-hundred day moving average price is $26.82. The stock has a market cap of $1.14 billion, a PE ratio of -20.64 and a beta of 1.77.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last released its quarterly earnings results on Thursday, May 23rd. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.74). The firm had revenue of $28.43 million for the quarter, compared to the consensus estimate of $35.78 million. Calliditas Therapeutics AB (publ) had a negative return on equity of 160.87% and a negative net margin of 40.19%. As a group, analysts expect that Calliditas Therapeutics AB will post -0.86 earnings per share for the current fiscal year.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.